'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Clinical Trials by G7 Countries: Proportion of Tardive Dyskinesia to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Tardive Dyskinesia to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in E7 Countries 17
Clinical Trials in E7 Countries by Trial Status 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Tardive Dyskinesia Therapeutics Clinical Trials 26
Prominent Drugs 27
Latest Clinical Trials News on Tardive Dyskinesia 28
Sep 22, 2016: Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD) 28
Clinical Trial Profile Snapshots 29
Appendix 54
Abbreviations 54
Definitions 54
Research Methodology 55
Secondary Research 55
About GlobalData 56
Contact Us 56
Disclaimer 56
Source 57
List of Tables
Tardive Dyskinesia Therapeutics, Global, Clinical Trials by Region, 2016* 6
Tardive Dyskinesia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Tardive Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Tardive Dyskinesia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 9
Tardive Dyskinesia Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Tardive Dyskinesia Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Tardive Dyskinesia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Proportion of Tardive Dyskinesia to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 13
Tardive Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
Tardive Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
Proportion of Tardive Dyskinesia to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 16
Tardive Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17
Tardive Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 18
Tardive Dyskinesia Therapeutics, Global, Clinical Trials by Phase, 2016* 19
Tardive Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 20
Tardive Dyskinesia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21
Tardive Dyskinesia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22
Tardive Dyskinesia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23
Tardive Dyskinesia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 24
Tardive Dyskinesia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25
Tardive Dyskinesia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26
Tardive Dyskinesia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27
List of Figures
Tardive Dyskinesia Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Tardive Dyskinesia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Tardive Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Tardive Dyskinesia Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 9
Tardive Dyskinesia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Tardive Dyskinesia Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Tardive Dyskinesia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Proportion of Tardive Dyskinesia to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 13
Tardive Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
Tardive Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
Proportion of Tardive Dyskinesia to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 16
Tardive Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17
Tardive Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 18
Tardive Dyskinesia Therapeutics, Global, Clinical Trials by Phase (%), 2016* 19
Tardive Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 20
Tardive Dyskinesia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21
Tardive Dyskinesia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22
Tardive Dyskinesia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23
Tardive Dyskinesia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 24
Tardive Dyskinesia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25
Tardive Dyskinesia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26
Tardive Dyskinesia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27
GlobalData Methodology 55